The estimated Net Worth of Mark Schoenberg is at least $3.11 millió dollars as of 10 June 2024. Mark Schoenberg owns over 10,000 units of UroGen Pharma Ltd stock worth over $2,063,725 and over the last 6 years he sold URGN stock worth over $242,864. In addition, he makes $800,908 as Chief Medical Officer at UroGen Pharma Ltd.
Mark has made over 32 trades of the UroGen Pharma Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of URGN stock worth $138,100 on 10 June 2024.
The largest trade he's ever made was exercising 122,677 units of UroGen Pharma Ltd stock on 20 January 2023 worth over $613,385. On average, Mark trades about 4,752 units every 52 days since 2019. As of 10 June 2024 he still owns at least 149,437 units of UroGen Pharma Ltd stock.
You can see the complete history of Mark Schoenberg stock trades at the bottom of the page.
Dr. Mark P. Schoenberg, M.D. is Chief Medical Officer of the Company. has served as our Chief Medical Officer since December 2017 and, prior to that, served as our Medical Director since February 2016. Dr. Schoenberg has over 20 years of experience in clinical practice and research focused on the care of patients with all forms of bladder cancer. Since April 2014, Dr. Schoenberg has been University Professor and Chairman of the Urology Department at The Montefiore Medical Center for The Albert Einstein College of Medicine of Yeshiva University. Prior to joining Montefiore, from 2005 to 2014, Dr. Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins Hospital. Dr. Schoenberg is also the past chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, the author of The Guide to Living with Bladder Cancer, co-editor of The Textbook of Bladder Cancer, a contributor to Campbell’s Urology and a past Senior Editor of the journal Seminars in Urologic Oncology. Dr. Schoenberg received his M.D. (Alpha Omega Alpha) from the University of Texas Health Sciences Center and completed his residency in General Surgery and Urology at the Hospital of The University of Pennsylvania, where he served as chief resident and urology instructor, before completing basic research and clinical urologic oncology fellowships at Johns Hopkins under the auspices of The American Cancer Society. Dr. Schoenberg is a fellow of the American College of Surgeons, as well as a member of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association.
As the Chief Medical Officer of UroGen Pharma Ltd, the total compensation of Mark Schoenberg at UroGen Pharma Ltd is $800,908. There are 2 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.
Mark Schoenberg is 62, he's been the Chief Medical Officer of UroGen Pharma Ltd since 2017. There are 4 older and 11 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.
Mark's mailing address filed with the SEC is 400 ALEXANDER PARK DRIVE, , PRINCETON, NJ, 08540.
Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun és Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
UroGen Pharma Ltd executives and other stock owners filed with the SEC include: